Lumbrokinase is a new product which shows promise in dissolving clots without the risk of hemorrhage. Clinical studies have shown that stroke patients on Lumbrokinase within one month following a stroke showed almost complete recovery. Boluoke, the trade name for Lumbrokinase, is safe, effective and available OTC.
Lumbrokinase also referred to as: earthworm powder, fibrinolytic enzymes, earthworm powder enzymes (EPE), e-PPA, Boluoke. The earthworm whose scientific name is Lumbricus rubellus has been used for centuries in the Far East as a traditional medicine. The earthworm's ability to break down fibrin was reported by Fredericq and Krukenberg in the 1920's. Since then, some Japanese scholar like Mihara Hisashi succeeded in extracting fibrin dissolving enzyme from Lumbricus rubellus, and also found that this enzyme consists of six proteolytic enzymes, which are collectively named Lumbrokinase. Lumbrokinase also overcame the adverse effects of bleeding by having a uniquely high affinity for fibrin.
This preparation may have a significant effect in the prevention and treatment of ischemic cerebrovascular disease. Boluoke can be applied widely in the treatment of myocardiac infarction, vascular sudden deafness, retinal artery and vein occlusion induced blindness, and pulmonary infarction. It is a good adjunctive treatment for patients who are on or have had EDTA chelation therapy or hyperbaric oxygen therapy.
As Boluoke is easily taken, has few side effects and no hemorrhage risk, it can be used as long-term anticoagulant agent to apply in accessory treatment and complicating disease prevention after some clinical operations, such as catheterization procedures. Since Boluoke has no gastrointestinal reaction, it can be used as a substitute for patients who are unable to tolerate aspirin.
Boluoke is also used in the prevention and treatment of hypercoagulability associated with some chronic diseases, for example: diabetes mellitus, pulmonary heart disease, atrial fibrillation, malignant tumor, systemic lupus erythematosus, polycythemia vera, thrombocythemia, glomerulonephritis, hemolytic anemia, liver disease and preeclampsia. Being an unique oral anticoagulant and thrombolytic drug that possesses urokinase and t-PA activities, Boluoke can be applied in a combined treatment for thrombosis disease with other anticoagulant medicine.
For acute conditions: 2 capsules tid 30 minutes before meals for 3-4 weeks or as advised by your health care professional. For maintenance and prevention: 1 capsule 1-3 times per day 30 minutes before meals.
Since 1990, affiliated Xuanwu Hospital of Capital Medical College, Jiangxi Provincial People's Hospital and No.2 Affiliated Hospital of Jiangxi Medical College have studied the clinical manifestations and the clotting characteristics of 453 patients with ischemic cerebrovascular disease by randomized double-blinded method. The results indicated that the total effective rate is 93% and the significant response rate is 73%.
Organized by Chinese Medical Society, a collaborative group of 16 hospitals has performed a phase III clinical trial of Boluoke capsule in treating ischemic cerebrovascular disease from June 1992 to December 1993. Totally, 1560 patients were studied according to "the censorship and approval regulations of new drugs "to further verify the clinical efficacy and investigate the adverse effects. The total effective rate is 88% and the significant response rate is 68 %. These results all showed that Boluoke capsule is a promising new anti-thrombotic drug with no obvious toxic or adverse effects, worthy of extensive application.
Recently a new enzyme with potent fibrinolytic activity that rivals pharmaceutical agents has been discovered and shows great potential in providing support for hypercoagulative states. This all natural enzyme, Nattokinase, is derived from fermented soy and the bacteria Bacillus natto. Already, backed by research, Nattokinase shows promise in supporting areas such as cardiovascular disease, stroke, angina, venous stasis, thrombosis, emboli, atherosclerosis, fibromyalgia/chronic Fatigue, claudication, retinal pathology, hemorrhoid, varicose veins, soft tissue rheumatisms, muscle spasm, poor healing, chronic inflammation and pain, peripheral vascular disease, hypertension, tissue oxygen deprivation, infertility, and other gynecology conditions (e.g. endometriosis, uterine fibroids). Nattokinase is inexpensive and available from Allergy Research Group.
Various products containing nattokinase have different Fibrin Units (FU) of activity per capsule or tablet. The recommended maintenance dose is 1000 F.U. bid and the therapeutic dose is 2000 FU bid.
Serrapeptase, also known as Serratia peptidase, is a proteolytic enzyme isolated from the non-pathogenic enterobacteria Serratia E15. When consumed in unprotected tablets or capsules, the enzyme is destroyed by acid in the stomach. However, enterically-coated tablets enable the enzyme to pass through the stomach unchanged, and be absorbed in the intestine.
Clinical studies show that serrapeptase induces fibrinolytic, anti-inflammatory and anti-edemic (prevents swelling and fluid retention) activity in a number of tissues, and that its anti-inflammatory effects are superior to other proteolytic enzymes.
Besides reducing inflammation, one of serrapeptase's most profound benefits is reduction of pain, due to its ability to block the release of pain-inducing amines from inflamed tissues. Physicians throughout Europe and Asia have recognized the anti-inflammatory and pain-blocking benefits of this naturally occurring substance and are using it in treatment as an alternative to salicylates, ibuprofen and other NSAIDs.
The total dose of serrapeptase per day is between 10 and 30mg on an empty stomach, preferably in three divided doses. The cost should not be prohibitive, as might be expected from looking at some of the newer products on the market.